Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)

  Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World
                 Conference on Interventional Oncology (WCIO)

Duration of RFA Procedure Correlates with an Overall Survival Benefit

PR Newswire

LAWRENCEVILLE, N.J., May 17, 2013

LAWRENCEVILLE, N.J., May 17, 2013 /PRNewswire/ --Celsion Corporation (NASDAQ:
CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013
WCIO Program Chairman and the Director of the Division of Diagnostic Imaging
and Intervention at Pisa University School of Medicine in Italy and Lead
European Principal Investigator for the HEAT Study and Professor Ronnie T.P.
Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of
Hong Kong and Lead Asia Pacific Principal Investigator for the HEAT Study
conducted separate scientific discussions reviewing the clinical trial results
from the Company's Phase III HEAT Study including new emerging findings from
the HEAT Study post-hoc analysis at the 9^th Annual Meeting of the World
Conference on Interventional Oncology, which is being held on May 16 to 20,
2013 in New York City. The new post-hoc findings suggest that optimized
heating cycles markedly improve radiofrequency ablation (RFA) plus ThermoDox's
potential for clinically relevant improved progression free survival (PFS) and
Overall Survival (OS) outcomes. Professors Poon and Lencioni both concluded
that the findings warrant further investigation and development of ThermoDox
as a first line treatment for HCC when combined with RFA. The slide
presentations are available on the Events and Presentations page on the
Celsion website.

"I was pleased to discuss this post-hoc analysis of a large subgroup of
patients from the Phase III HEAT Study at the WCIO Conference in New York
which may be indicating a meaningful clinical benefit in both PFS and Overall
Survival in patients who received an optimized RFA procedure," said Professor
Lencioni. "It would appear that the duration of heat from the RFA procedure
is a key factor in a successful clinical outcome when combined with ThermoDox
as suggested by this analysis. These findings may offer a path forward to
potentially offering an important new therapy for HCC patients with limited
treatment options."

"This subgroup analysis of approximately 300 patients, although not
statistically significant, is nevertheless demonstrating a strong positive
trend in both PFS and Overall Survival in ThermoDox® treated patients when
heating cycles from the RFA procedure were optimized," said Professor Ronnie
Poon. "What we have learned from the HEAT Study is that there is a large
cohort of patients that appear to have demonstrated an important benefit from
ThermoDox provided the RFA treatment time is properly applied. These findings
are quite encouraging and should be confirmed with additional non-clinical
studies and clinical trial data."

The data from the HEAT Study post-hoc analysis presented by Professors
Lencioni and Poon demonstrate that ThermoDox markedly improves PFS and OS in
patients with a single lesion if their lesions undergo RFA for 45 minutes or
more. These findings apply to HCC lesion regardless of size and represent a
subgroup of approximately 300 patients or 42% of the patients in the HEAT
Study. The post-hoc analysis completed by the Company to-date indicates that
there may be a large patient cohort that benefited from RFA plus ThermoDox
regardless of lesion size.

  oIn the patient subgroup treated in the ThermoDox arm whose RFA procedure
    lasted longer than 45 minutes and was completed within 90 minutes (40% of
    single lesion patients), Overall Survival improved by 66% (Hazard Ratio of
    0.602) when compared to the control arm of RFA treatment only.
  oIn the patient subgroup treated in the ThermoDox arm whose RFA procedure
    lasted longer than 90 minutes (23% of single lesion patients), Overall
    Survival almost doubled (Hazard Ratio of 0.508) when compared to the
    control arm of RFA treatment only.
  oWhen combined, these two subgroups show clinical results that indicated a
    53% improvement in Overall Survival, a Hazard Ratio of 0.65, and a
    P[value] = 0.105.
  oIn contrast, the patient subgroup treated with ThermoDox whose RFA
    procedure lasted less than 45 minutes in duration (37% of single lesion
    patients) indicated that the control arm had an improved Overall Survival
    benefit when compared to the ThermoDox arm.
  oThe Hazard Ratios reported above should be viewed with caution since they
    are not statistically significant and the HEAT Study has not reached its
    median point for Overall Survival analysis. Celsion will continue
    following all patients enrolled in the HEAT Study to the secondary
    endpoint, Overall Survival, and update its subgroup analysis based on RFA
    heating duration.

Dr. Lencioni's presentation, titled "Advances in Image-Guided Ablation" was
held in Plenary Session: Multidisciplinary State-of-the Art: HCC and Professor
Poon's presentation, titled "Thermally Sensitive Drug Carriers" was held in
Concurrent Session: New Drugs/New Carriers/New Devices. Both presentations
were held on Thursday, May 16, 2013 and are available on the Company's website
at www.celsion.com under "News & Investor Info – Events & Presentations."

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology. Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford. For more information on Celsion, visit
our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; HEAT Study data is subject to further
verification and review by the HEAT Study Data Management Committee; the need
for Celsion to evaluate its future development plans; termination of the
Technology Development Contract or collaboration between Celsion and HISUN at
any time; possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or licenses;
possible actions by customers, suppliers, competitors, regulatory authorities;
and other risks detailed from time to time in the Celsion 's periodic reports
and prospectuses filed with the Securities and Exchange Commission. Celsion
assumes no obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Sr. Vice President — Corporate
Strategy and Investor Relations

SOURCE Celsion Corporation

Website: http://www.celsion.com
Press spacebar to pause and continue. Press esc to stop.